Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Journal Article (Letter)
Full Text
Duke Authors
Cited Authors
- Willett, CG; Boucher, Y; Duda, DG; di Tomaso, E; Munn, LL; Tong, RT; Kozin, SV; Petit, L; Jain, RK; Chung, DC; Sahani, DV; Kalva, SP; Cohen, KS; Scadden, DT; Fischman, AJ; Clark, JW; Ryan, DP; Zhu, AX; Blaszkowsky, LS; Shellito, PC; Mino-Kenudson, M; Lauwers, GY
Published Date
- November 1, 2005
Published In
Volume / Issue
- 23 / 31
Start / End Page
- 8136 - 8139
PubMed ID
- 16258121
International Standard Serial Number (ISSN)
- 0732-183X
Digital Object Identifier (DOI)
- 10.1200/JCO.2005.02.5635
Language
- eng
Conference Location
- United States